Irinotecan delivery by microbubble-assisted ultrasound: In vitro validation and a pilot preclinical study

Molecular Pharmaceutics

Volumn 10, Issue 7, 2013, Pages 2667-2675

  Escoffre, J M ^a,c   Novell, A ^a   Serriere S ^a   Lecomte, T ^a,b   Bouakaz, A ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

anticancer therapy; irinotecan; microbubbles; sonoporation; ultrasound; ultrasound imaging

Indexed keywords

IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MICROBUBBLE; MICROBUBBLE ASSISTED ULTRASOUND; MOUSE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR XENOGRAFT; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MALE; MICE, NUDE; MICROBUBBLES; ULTRASONICS;

EID: 84879734680     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400081b     Document Type: Article

References (62)

1. Fujita, K.; Sparreboom, A. Pharmacogenetics of irinotecan disposition and toxicity: a review Curr. Clin. Pharmacol. 2010, 5, 209-17
2. Weekes, J.; Ho, Y. H.; Sebesan, S.; Ong, K.; Lam, A. K. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-Crystallin expression Int. J. Colorectal Dis. 2010, 25, 907
3. Weekes, J.; Lam, A. K.; Sebesan, S.; Ho, Y. H. Irinotecan therapy and molecular targets in colorectal cancer: a systemic review World J. Gastroenterol. 2009, 15, 3597-602
4. Vredenburgh, J. J.; Desjardins, A.; Reardon, D. A.; Friedman, H. S. Experience with irinotecan for the treatment of malignant glioma Neuro Oncol. 2009, 11, 80-91
5. Jakobsen, J. N.; Hasselbalch, B.; Stockhausen, M. T.; Lassen, U.; Poulsen, H. S. Irinotecan and bevacizumab in recurrent glioblastoma multiforme Expert Opin. Pharmacother. 2011, 12, 825-33
6. Hatfield, M. J.; Tsurkan, L.; Garrett, M.; Shaver, T. M.; Hyatt, J. L.; Edwards, C. C.; Hicks, L. D.; Potter, P. M. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11 Biochem. Pharmacol. 2011, 81, 24-31
7. Ghosh, S. Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA Physiol. Genom. 2000, 2, 1-8
8. Wang, W.; Ghandi, A.; Liebes, L.; Louie, S. G.; Hofman, F. M.; Schonthal, A. H.; Chen, T. C. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation J. Neurosurg. 2011, 114, 689-94
9. Sanghani, S. P.; Quinney, S. K.; Fredenburg, T. B.; Sun, Z.; Davis, W. I.; Murry, D. J.; Cummings, O. W.; Seitz, D. E.; Bosron, W. F. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis Clin. Cancer Res. 2003, 9, 4983-91
10. Mathijssen, R. H.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin. Cancer Res. 2001, 7, 2182-94
11. Ikeguchi, M.; Arai, Y.; Maeta, Y.; Ashida, K.; Katano, K.; Wakatsuki, T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer Surg. Today 2011, 41, 1196-9
12. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin Cancer Res. 1989, 49, 5077-82
13. Goldwasser, F.; Bae, I.; Valenti, M.; Torres, K.; Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen Cancer Res. 1995, 55, 2116-21
14. Candeil, L.; Gourdier, I.; Peyron, D.; Vezzio, N.; Copois, V.; Bibeau, F.; Orsetti, B.; Scheffer, G. L.; Ychou, M.; Khan, Q. A.; Pommier, Y.; Pau, B.; Martineau, P.; Del Rio, M. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int. J. Cancer 2004, 109, 848-54
15. Douillard, J. Y.; Cunningham, D.; Roth, A. D.; Navarro, M.; James, R. D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 2000, 355, 1041-7
16. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N. Engl. J. Med. 2000, 343, 905-14
17. Van Cutsem, E.; Dirix, L.; Van Laethem, J. L.; Van Belle, S.; Borner, M.; Gonzalez Baron, M.; Roth, A.; Morant, R.; Joosens, E.; Gruia, G.; Sibaud, D.; Bleiberg, H. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study Br. J. Cancer 2005, 92, 1055-62
18. Ducreux, M.; Ychou, M.; Seitz, J. F.; Bonnay, M.; Bexon, A.; Armand, J. P.; Mahjoubi, M.; Mery-Mignard, D.; Rougier, P. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer J. Clin. Oncol. 1999, 17, 2901-8
19. Cassinello, J.; Lopez-Alvarez, P.; Martinez-Guisado, A.; Valladares, M.; Huidobro, G.; Lopez, R.; Bohn, U.; Sevilla, I.; Ballesteros, P.; Jorge, M.; Perez-Carrion, R.; Fernandez, J. L.; Dorta, J. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer Med. Oncol. 2003, 20, 37-43
20. Tobin, P.; Rivory, L.; Clarke, S. Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) Clin. Pharmacol. Ther. 2004, 76, 505-6 author reply 507-8
21. Deckers, R.; Moonen, C. T. Ultrasound triggered, image guided, local drug delivery J. Controlled Release 2010, 148, 25-33
22. Escoffre, J. M.; Zeghimi, A.; Novell, A.; Bouakaz, A. In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects Curr. Gene Ther. 2012, 13, 2-14
23. Frenkel, V. Ultrasound mediated delivery of drugs and genes to solid tumors Adv. Drug Delivery Rev. 2008, 60, 1193-208
24. Doinikov, A. A.; Bouakaz, A. Acoustic microstreaming around an encapsulated particle J. Acoust. Soc. Am. 2010, 127, 1218-27
25. Leong, T.; Collis, J.; Manasseh, R.; Ooi, A.; Novell, A.; Bouakaz, A.; Ashokkumar, M.; Kentish, S. The role of surfactant headgroup, chain length, and cavitation microstreaming on the growth of bubbles by rectified diffusion J. Phys. Chem. C 2011, 115, 24310-24316
26. Ohl, C. D.; Wolfrum, B. Detachment and sonoporation of adherent HeLa-cells by shock wave-induced cavitation Biochim. Biophys. Acta 2003, 1624, 131-8
27. Ohl, C. D.; Arora, M.; Ikink, R.; de Jong, N.; Versluis, M.; Delius, M.; Lohse, D. Sonoporation from jetting cavitation bubbles Biophys. J. 2006, 91, 4285-95
28. Meijering, B. D.; Juffermans, L. J.; van Wamel, A.; Henning, R. H.; Zuhorn, I. S.; Emmer, M.; Versteilen, A. M.; Paulus, W. J.; van Gilst, W. H.; Kooiman, K.; de Jong, N.; Musters, R. J.; Deelman, L. E.; Kamp, O. Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation Circ. Res. 2009, 104, 679-87
29. Zeghimi, A.; Uzbekov, R.; Arbeille, B.; Escoffre, J. M.; Bouakaz, A. In Ultrasound modifications of cell membranes and organelles induced by sonoporation; IEEE International Ultrasonics Symposium Proceedings, Dresden, Germany, 2012; 2045-2048.
30. Choijamts, B.; Naganuma, Y.; Nakajima, K.; Kawarabayashi, T.; Miyamoto, S.; Tachibana, K.; Emoto, M. Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft Cancer Sci. 2011, 102, 452-9
31. Escoffre, J. M.; Piron, J.; Novell, A.; Bouakaz, A. Doxorubicin delivery into tumor cells with ultrasound and microbubbles Mol. Pharmaceutics 2011, 8, 799-806
32. Geers, B.; Lentacker, I.; Sanders, N. N.; Demeester, J.; Meairs, S.; De Smedt, S. C. Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery J. Controlled Release 2011, 152, 249-56
33. Mohan, P.; Rapoport, N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking Mol. Pharmaceutics 2010, 7, 1959-73
34. Escoffre, J. M.; Novell, A.; Piron, J.; Zeghimi, A.; Doinikov, A. A.; Bouakaz, A. Microbubble attenuation and destruction: Are they involved in sonoporation efficiency? IEEE Trans. Ultrason Ferroelectr. Freq. Control 2013, 60, 46-52
35. Escoffre, J. M.; Mannaris, C.; Geers, B.; Novell, A.; Lentacker, I.; Averkiou, M. A.; Bouakaz, A. Doxorubicin liposome-loaded microbubbles for contrast imaging and ultrasound-triggered drug delivery IEEE Trans. Ultrason. Ferroelectr. Freq. Control 2013, 60, 78-87
36. Lentacker, I.; Geers, B.; Demeester, J.; De Smedt, S. C.; Sanders, N. N. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved Mol. Ther. 2010, 18, 101-8
37. Kaneda, N.; Nagata, H.; Furuta, T.; Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse Cancer Res. 1990, 50, 1715-20
38. Ayers, G. D.; McKinley, E. T.; Zhao, P.; Fritz, J. M.; Metry, R. E.; Deal, B. C.; Adlerz, K. M.; Coffey, R. J.; Manning, H. C. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements J. Ultrasound Med. 2010, 29, 891-901
39. Novell, A.; Escoffre, J. M.; Bouakaz, A. Ultrasound contrast imaging in cancer-Technical aspects and prospects Curr. Mol. Imaging 2013, 2, 77-88
40. Needles, A.; Arditi, M.; Rognin, N. G.; Mehi, J.; Coulthard, T.; Bilan-Tracey, C.; Gaud, E.; Frinking, P.; Hirson, D.; Foster, F. S. Nonlinear contrast imaging with an array-based micro-ultrasound system Ultrasound Med. Biol. 2010, 36, 2097-106
41. Cemazar, M.; Golzio, M.; Escoffre, J. M.; Couderc, B.; Sersa, G.; Teissie, J. In vivo imaging of tumor growth after electrochemotherapy with cisplatin Biochem. Biophys. Res. Commun. 2006, 348, 997-1002
42. Geers, B.; Lentacker, I.; Alonso, A.; Sanders, N. N.; Demeester, J.; Meairs, S.; De Smedt, S. C. Elucidating the mechanisms behind sonoporation with adeno-associated virus-loaded microbubbles Mol. Pharmaceutics 2011, 8, 2244-51
43. Kaddur, K.; Lebegue, L.; Tranquart, F.; Midoux, P.; Pichon, C.; Bouakaz, A. Transient transmembrane release of green fluorescent proteins with sonoporation IEEE Trans. Ultrason. Ferroelectr. Freq. Control 2010, 57, 1558-67
44. Tran, T. A.; Roger, S.; Le Guennec, J. Y.; Tranquart, F.; Bouakaz, A. Effect of ultrasound-activated microbubbles on the cell electrophysiological properties Ultrasound Med. Biol. 2007, 33, 158-63
45. Juffermans, L. J.; Kamp, O.; Dijkmans, P. A.; Visser, C. A.; Musters, R. J. Low-intensity ultrasound-exposed microbubbles provoke local hyperpolarization of the cell membrane via activation of BK(Ca) channels Ultrasound Med. Biol. 2008, 34, 502-8
46. Derieppe, M.; Yudina, A.; Lepetit-Coiffe, M.; de Senneville, B. D.; Bos, C.; Moonen, C. Real-Time Assessment of Ultrasound-Mediated Drug Delivery Using Fibered Confocal Fluorescence Microscopy Mol. Imaging Biol. 2013, 15, 3-11
47. Mehier-Humbert, S.; Bettinger, T.; Yan, F.; Guy, R. H. Plasma membrane poration induced by ultrasound exposure: implication for drug delivery J. Controlled Release 2005, 104, 213-22
48. van Wamel, A.; Kooiman, K.; Harteveld, M.; Emmer, M.; ten Cate, F. J.; Versluis, M.; de Jong, N. Vibrating microbubbles poking individual cells: drug transfer into cells via sonoporation J. Controlled Release 2006, 112, 149-55
49. Bohmer, M. R.; Chlon, C. H.; Raju, B. I.; Chin, C. T.; Shevchenko, T.; Klibanov, A. L. Focused ultrasound and microbubbles for enhanced extravasation J. Controlled Release 2010, 148, 18-24
50. Gordon, M. S.; Mendelson, D. S.; Kato, G. Tumor angiogenesis and novel antiangiogenic strategies Int. J. Cancer 2010, 126, 1777-87
51. Horie, S.; Watanabe, Y.; Ono, M.; Mori, S.; Kodama, T. Evaluation of antitumor effects following tumor necrosis factor-alpha gene delivery using nanobubbles and ultrasound Cancer Sci. 2011, 102, 2082-2089
52. Du, L.; Jin, Y.; Zhou, W.; Zhao, J. Ultrasound-triggered drug release and enhanced anticancer effect of doxorubicin-loaded poly(D,L-lactide-co-glycolide) -methoxy-poly(ethylene glycol) nanodroplets Ultrasound Med. Biol. 2011, 37, 1252-8
53. Roger, E.; Lagarce, F.; Benoit, J. P. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration Eur. J. Pharmaceutics Biopharmaceutics 2011, 79, 181-8
54. Kuroda, J.; Kuratsu, J.; Yasunaga, M.; Koga, Y.; Saito, Y.; Matsumura, Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma Int. J. Cancer 2009, 124, 2505-11
55. Ebrahimnejad, P.; Dinarvand, R.; Jafari, M. R.; Tabasi, S. A.; Atyabi, F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38 Int. J. Pharmaceutics 2011, 406, 122-7
56. Verreault, M.; Strutt, D.; Masin, D.; Anantha, M.; Waterhouse, D.; Yapp, D. T.; Bally, M. B.; Irinophore, C. A lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model J. Controlled Release 2012, 158, 34-43
57. Krauze, M. T.; Noble, C. O.; Kawaguchi, T.; Drummond, D.; Kirpotin, D. B.; Yamashita, Y.; Kullberg, E.; Forsayeth, J.; Park, J. W.; Bankiewicz, K. S. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts Neuro Oncol. 2007, 9, 393-403
58. Ramsay, E. C.; Anantha, M.; Zastre, J.; Meijs, M.; Zonderhuis, J.; Strutt, D.; Webb, M. S.; Waterhouse, D.; Bally, M. B. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 2008, 14, 1208-17
59. Baker, J. H.; Lam, J.; Kyle, A. H.; Sy, J.; Oliver, T.; Co, S. J.; Dragowska, W. H.; Ramsay, E.; Anantha, M.; Ruth, T. J.; Adam, M. J.; Yung, A.; Kozlowski, P.; Minchinton, A. I.; Ng, S. S.; Bally, M. B.; Yapp, D. T. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin Clin. Cancer Res. 2008, 14, 7260-71
60. Sadzuka, Y.; Hirotsu, S.; Hirota, S. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38 Jpn. J. Cancer Res. 1999, 90, 226-32
61. Ramsay, E.; Alnajim, J.; Anantha, M.; Zastre, J.; Yan, H.; Webb, M.; Waterhouse, D.; Bally, M. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur. J. Pharmaceutics Biopharmaceutics 2008, 68, 607-17
62. Lin, C. Y.; Li, J. R.; Tseng, H. C.; Wu, M. F.; Lin, W. L. Enhancement of focused ultrasound with microbubbles on the treatments of anticancer nanodrug in mouse tumors Nanomedicine 2012, 8, 900-7